Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
MWN-AI** Summary
Nyxoah SA, a medical technology firm based in Mont-Saint-Guibert, Belgium, has announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference scheduled for March 16-19, 2026. The company, which specializes in innovative solutions for Obstructive Sleep Apnea (OSA), will feature a corporate presentation by CEO Olivier Taelman on March 16 at 8:40 am ET. This presentation aims to inform stakeholders about Nyxoah’s advancements and future plans, with a webcast available on the company's Investor Relations website.
Nyxoah is known for its lead product, the Genio system, which offers a groundbreaking leadless and battery-free hypoglossal neurostimulation therapy for OSA, the most common form of sleep-disordered breathing. The system, which received its CE mark in 2019 following successful results from the BLAST OSA study, addresses a critical health issue associated with increased mortality and cardiovascular risks. Recently, Nyxoah expanded its treatment indications to include Complete Concentric Collapse patients, a market segment often overlooked by competitors.
The company’s strong performance includes a successful IPO on Euronext Brussels in September 2020 and on NASDAQ in July 2021. The FDA also recently approved the Genio system for use in a select group of adult patients with moderate to severe OSA.
Investors and analysts can expect insights into the firm's commercialization strategy and the broader implications of the Genio system in treating OSA at the conference. As Nyxoah continues to navigate the complexities of the medical device landscape, it is critical for stakeholders to note that the future outlook, as outlined by the company, contains inherent risks and uncertainties that could impact its trajectory.
MWN-AI** Analysis
Nyxoah SA is gearing up for its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, a key event that could significantly influence its market positioning. The conference, set for March 16-19, 2026, offers a platform for Nyxoah to showcase its innovative Genio system—a leadless and battery-free hypoglossal neurostimulation device aimed at treating Obstructive Sleep Apnea (OSA).
This conference is critical for Nyxoah as it attempts to expand its visibility with institutional investors, especially following its recent FDA approval for a subset of adult OSA patients. The positive trajectory exhibited by the company, highlighted by successful trials including the DREAM IDE and BETTER SLEEP studies, positions it favorably in a competitive landscape marred by both regulatory and market pressures.
Investors should note the competitive edge Nyxoah has acquired through its CE mark approvals and the promise of addressing Complete Concentric Collapse patients, which competitors currently overlook. However, the company operates in a highly regulated environment; thus, the forward-looking statements regarding its future performance should be approached with caution, given their inherent uncertainties.
As Nyxoah continues to engage with potential investors during the conference, market participants should closely monitor its developments, particularly any announcements related to potential partnerships or funding that could bolster its commercialization strategy. The upcoming presentation by CEO Olivier Taelman should detail not only the company’s innovations but also its tactical roadmap for growth in new markets, including the U.S.
For those considering an investment, it may be prudent to analyze Nyxoah’s capital structure, recent performance metrics, and guidance closely following the conference, as these insights may provide clarity on the stock’s future trajectory amid ongoing developments in the MedTech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, which takes place March 16 – 19, 2026.
Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 16, 2026, at 8:40 am ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1x1 meetings with institutional investors.
Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s
Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
FAQ**
Can you provide an update on the current market reception and sales performance of the Genio system since Nyxoah SA NYXH received FDA approval for certain OSA patients in August 2025?
How does Nyxoah SA NYXH plan to differentiate the Genio system from competitors in the growing OSA treatment market, especially now that you have expanded indications?
What are the key milestones Nyxoah SA NYXH aims to achieve in 2026 to enhance the commercialization of the Genio system in both Europe and the U.S.?
Based on the results of the recent studies, what is Nyxoah SA NYXH's strategy for addressing potential risks and uncertainties outlined in your SEC filings to ensure sustained growth and innovation?
**MWN-AI FAQ is based on asking OpenAI questions about Nyxoah SA (NASDAQ: NYXH).
NASDAQ: NYXH
NYXH Trading
-5.81% G/L:
$3.24 Last:
22,444 Volume:
$3.49 Open:
